Commerce Dashboard

Cadila Pharmaceuticals Ltd.

Go Back

Cadila Pharmaceuticals Ltd.

  • Started production in 1952
  • India's first indigenous manufacturer of natural Streptokinase - STPase
  • Introduced world's first IMMUVAC, a unique Immunomodulator
  • launched NEVA HIV - world's first whole blood rapid HIV detection kit

Cadila Pharmaceuticals Ltd is one of the largest privately held pharmaceutical companies in India, headquartered at Ahmedabad, Gujarat. Over the last six decades, the company has been developing and manufacturing pharmaceutical products in India and selling and distributing these in over eighty-five other countries around the world.

Focused strongly on innovation and research, the company is present in more than forty-five therapeutic areas spread across twelve specialities, including cardiovascular, gastrointestinal, analgesics, haematinics, anti-infectives and antibiotics, respiratory agents, antidiabetics and immunologicals.

At Cadila Pharmaceuticals, R&D is at the core of all its initiatives, be it biotechnology, APIs, formulations, plant tissue culture or phytochemistry.

More than 300 scientists in its various R&D setups reinforce the competitiveness of research in the therapeutic areas which have high unmet medical needs.


Cadila Pharmaceuticals: The care continues

2013 Cadila Pharmaceuticals launches Mycidac-C- first in the world innovative and affordable product for the patients suffering from lung cancers.
1999 Cadila Pharmaceuticals Ltd. ventures in the US market by establishing CPL Inc
1982 Karnavati Engineering Limited (KEL), Kadi the machinery-manufacturing arm of Cadila, commences operations
1967 Cadila shifts to its own factory premises with operations full-fledged spanning Production, Marketing, R&D
1952 Cadila starts production
India ranks 3rd worldwide for pharmaceutical production by volume and 14th by value. The country has an established domestic pharmaceutical industry, with a strong network of 3,000 drug companies and ~10,500 manufacturing units.